热门资讯> 正文

默克KGaA获得欧盟认可埃兹梅克利

2025-07-19 01:02

Merck KGaA (NYSE:MRK) said that the European Commission approved Ezmekly for treating symptomatic, inoperable plexiform neurofibromas in patients with neurofibromatosis type 1 who are 2 years old and older.
The approval was given to SpringWorks Therapeutics, a healthcare company associated with Merck.

More on Merck

Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue
Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Trump eyes drug, chip tariffs by month-end

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。